Alzheimer's Disease Neuroimaging Initiative (ADNI)

Introduction

Overview

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a landmark multi-center study launched in 2004 to define the progression of Alzheimer's Disease (AD).[@weiner2025] ADNI has become one of the most influential research programs in Alzheimer's Disease, with data from over 1,000 participants followed for more than 15 years.[@mueller2005] [@weiner2025]

Study Design

ADNI employs a longitudinal cohort design with three main diagnostic groups: [@mueller2005]

• Cognitively Normal (CN): Individuals with no cognitive impairment[@petersen2010]
• Mild Cognitive Impairment (MCI): Individuals with subtle cognitive deficits[@winblad2015]
• Alzheimer's Disease (AD): Individuals meeting clinical criteria for AD[@mckhann2011]

Key Objectives

Data Collection

Imaging Modalities

ADNI collects multiple imaging modalities: [@petersen2010]

• MRI: Structural brain imaging to measure hippocampal atrophy[@frisoni2010]
• PET: Amyloid and FDG-PET to assess amyloid burden and glucose metabolism[@klunk2004]
• PIB-PET: Pittsburgh compound B for amyloid imaging[@mathis2005]

Biospecimens

Introduction

Overview

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a landmark multi-center study launched in 2004 to define the progression of Alzheimer's Disease (AD).[@weiner2025] ADNI has become one of the most influential research programs in Alzheimer's Disease, with data from over 1,000 participants followed for more than 15 years.[@mueller2005] [@weiner2025]

Study Design

ADNI employs a longitudinal cohort design with three main diagnostic groups: [@mueller2005]

• Cognitively Normal (CN): Individuals with no cognitive impairment[@petersen2010]
• Mild Cognitive Impairment (MCI): Individuals with subtle cognitive deficits[@winblad2015]
• Alzheimer's Disease (AD): Individuals meeting clinical criteria for AD[@mckhann2011]

Key Objectives

Data Collection

Imaging Modalities

ADNI collects multiple imaging modalities: [@petersen2010]

• MRI: Structural brain imaging to measure hippocampal atrophy[@frisoni2010]
• PET: Amyloid and FDG-PET to assess amyloid burden and glucose metabolism[@klunk2004]
• PIB-PET: Pittsburgh compound B for amyloid imaging[@mathis2005]

Biospecimens

• Cerebrospinal Fluid (CSF): Biomarker analysis including [Aβ42](/proteins/amyloid-beta), [tau](/proteins/tau), and p-[tau](/proteins/tau)[@blennow2010]
• Blood: Plasma and serum biomarkers[@zetterberg2023]
• DNA/RNA: Genetic and genomic analyses[@saykin2010]

Major Findings

Biomarker Trajectories

ADNI established the hypothetical model of dynamic biomarkers showing that amyloid changes occur first, followed by neurodegeneration, then cognitive decline.[@jack2013a] This model has become foundational for understanding AD progression. [@winblad2015]

Amyloid Timeline

The accumulation of brain amyloid follows a predictable timeline, with amyloid plaques appearing 10-15 years before clinical symptoms.[@jansen2015] [@mckhann2011]

Neurodegeneration Markers

[Tau](/proteins/tau) and neurodegeneration markers correlate strongly with cognitive decline and are predictive of progression from MCI to AD.[@hansson2019] [@jack2010]

Blood Biomarkers

Recent ADNI analyses have validated plasma biomarkers including Aβ42/40 ratio, p-tau181, and [p-tau217](/biomarkers/p-tau-217) for early detection.[@schindler2019] [@jack2013]

Impact on Clinical Trials

ADNI has transformed clinical trial design by: [@aisen2011]

• Enabling enrichment strategies using biomarker-based participant selection[@visser2019]
• Reducing trial duration and sample sizes[@hendrix2015]
• Identifying optimal outcome measures[@cano2019]
• Validating surrogate endpoints[@aizenstein2014]

Participating Institutions

ADNI involves over 50 sites across North America, including major research universities and medical centers. The study is funded by the National Institute on Aging (NIA) and other partners. [@cummings2023]

Data Access

ADNI data are publicly available through the ADNI LONI Image and Data Archive (IDA), enabling researchers worldwide to conduct secondary analyses.[@adni] [@frisoni2010]

Future Directions

ADNI continues to evolve with: [@klunk2004]

• ADNI-GO and ADNI-2/3 phases[@weiner2017]
• Integration with other cohort studies
• Advanced biomarker development
• International collaboration (ADNI International)

See Also

• [PET Imaging in Neurodegeneration](/diagnostics/pet-imaging)

External Links

• [ADNI Official Website](https://adni.loni.usc.edu)
• [ADNI Data Archive](https://adni.loni.usc.edu/wp-content/uploads/2015/10/ADNI_GeneralCall.pdf)
• [ADNI Publications](https://adni.loni.usc.edu/courses-downloads/adni-publications/)

Background

The study of Alzheimer'S Disease Neuroimaging Initiative (Adni) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@mathis2005]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@blennow2010]

Additional evidence sources: [@zetterberg2023] [@saykin2010] [@jack2013a] [@jansen2015] [@hansson2019] [@schindler2019] [@visser2019] [@hendrix2015] [@cano2019] [@aizenstein2014] [@adni] [@weiner2017]

References